Prevalence of fractures in women with rheumatoid arthritis and/or systemic lupus erythematosus on chronic glucocorticoid therapy Epidemiology of musculoskeletal disorders

BMC Musculoskeletal Disorders

Volumn 16, Issue 1, 2015, Pages

  Rentero, Maria Luz ^a   Amigo, Encarna ^b   Chozas, Nicolas ^c   Fernández Prada, Manuel ^d   Silva Fernández, Lucia ^e   Abad Hernandez, Miguel Angel ^f   Rodriguez Barrera, Jose Maria ^g   Del Pino Montes, Javier ^h  

^a ELI LILLY AND COMPANY   (Spain)

^b Hospital de Lugo   (Spain)

^c HOSPITAL UNIVERSITARIO PUERTA DEL MAR   (Spain)

^d Hospital Sanitas La Moraleja   (Spain)

^e HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^f HOSPITAL VIRGEN DEL PUERTO   (Spain)

^g HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^h HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

Author keywords

Fracture; Glucocorticoid; Prevalence; Rheumatoid arthritis; Systemic lupus erythematosus

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; GLUCOCORTICOID; PARATHYROID HORMONE[1-34]; PREDNISONE; RALOXIFENE; STRONTIUM RANELATE; VITAMIN D;

ADULT; AGED; ARTICLE; BONE RADIOGRAPHY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DAS28; DISEASE SEVERITY; DRUG USE; FEMALE; FEMUR FRACTURE; FRACTURE; FRACTURE RISK ASSESSMENT; FRAGILITY FRACTURE; HIP FRACTURE; HUMAN; HUMERUS FRACTURE; LONG TERM CARE; MAJOR CLINICAL STUDY; MENOPAUSE; MIDDLE AGED; MORPHOMETRICS; PATIENT RISK; PELVIS FRACTURE; PREVALENCE; QUALITY OF LIFE; RADIUS FRACTURE; RHEUMATOID ARTHRITIS; RIB FRACTURE; RISK ASSESSMENT; SELF REPORT; SHORT FORM 36; SPAIN; SPINE FRACTURE; SYSTEMIC LUPUS ERYTHEMATOSUS; TIBIA FRACTURE; ARTHRITIS, RHEUMATOID; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPLICATION; LUPUS ERYTHEMATOSUS, SYSTEMIC; MULTICENTER STUDY; OSTEOPOROSIS; SPINAL FRACTURES; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ARTHRITIS, RHEUMATOID; CROSS-SECTIONAL STUDIES; FEMALE; GLUCOCORTICOIDS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; OSTEOPOROSIS; PREVALENCE; QUALITY OF LIFE; SPAIN; SPINAL FRACTURES;

EID: 84945191807     PISSN: None     EISSN: 14712474     Source Type: Journal    
DOI: 10.1186/s12891-015-0733-9     Document Type: Article

References (41)

1. Saag KG. Glucocorticoid-induced osteoporosis. Endocrinol Metab Clin North Am. 2003;32:135-57.
2. Weinstein RS. Is long-term glucocorticoid therapy associated with a high prevalence of asymptomatic vertebral fractures? Nat Clin Pract Endocrinol Metab. 2007;3:86-7.
3. LoCascio V, Bonucci E, Imbimbo B, Ballanti P, Adami S, Milani S, et al. Bone loss in response to long-term glucocorticoid therapy. Bone Miner. 1990;8:39-51.
4. van Staa TP, Laan RF, Barton IP, Cohen S, Reid DM, Cooper C. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum. 2003;48:3224-9.
5. Dirven L, van den Broek M, van Groenendael JH, de Beus WM, Kerstens PJ, Huizinga TW, et al. Prevalence of vertebral fractures in a disease activity steered cohort of patients with early active rheumatoid arthritis. BMC Musculoskelet Disord. 2012;13:125.
6. Ghazi M, Kolta S, Briot K, Fechtenbaum J, Paternotte S, Roux C. Prevalence of vertebral fractures in patients with rheumatoid arthritis: revisiting the role of glucocorticoids. Osteoporos Int. 2012;23:581-7.
7. El Maghraoui A, Rezqi A, Mounach A, Achemlal L, Bezza A, Ghozlani I. Prevalence and risk factors of vertebral fractures in women with rheumatoid arthritis using vertebral fracture assessment. Rheumatology (Oxford). 2010;49:1303-10.
8. Vis M, Haavardsholm EA, Bøyesen P, Haugeberg G, Uhlig T, Hoff M, et al. High incidence of vertebral and non-vertebral fractures in the OSTRA cohort study: a 5-year follow-up study in postmenopausal women with rheumatoid arthritis. Osteoporos Int. 2011;22:2413-9.
9. Almehed K, Hetényi S, Ohlsson C, Carlsten H, Forsblad-d'Elia H. Prevalence and risk factors of vertebral compression fractures in female SLE patients. Arthritis Res Ther. 2010;12:R153.
10. Bultink IE, Lems WF, Kostense PJ, Dijkmans BA, Voskuyl AE. Prevalence of and risk factors for low bone mineral density and vertebral fractures in patients with systemic lupus erythematosus. Arthritis Rheum. 2005;52:2044-50.
11. Borba VZ, Matos PG, da Silva Viana PR, Fernandes A, Sato EI, Lazaretti-Castro M. High prevalence of vertebral deformity in premenopausal systemic lupus erythematosus patients. Lupus. 2005;14:529-33.
12. Furukawa M, Kiyohara C, Horiuchi T, Tsukamoto H, Mitoma H, Kimoto Y, et al. Prevalence and risk factors of vertebral fracture in female Japanese patients with systemic lupus erythematosus. Mod Rheumatol. 2013;23:765-73.
13. Mendoza-Pinto C, García-Carrasco M, Sandoval-Cruz H, Muñoz-Guarneros M, Escárcega RO, Jiménez-Hernández M, et al. Risk factors of vertebral fractures in women with systemic lupus erythematosus. Clin Rheumatol. 2009;28:579-85.
14. García-Carrasco M, Mendoza-Pinto C, Riebeling C, Sandoval-Cruz M, Nava A, Etchegaray-Morales I, et al. Influence of prevalent vertebral fractures on the quality of life of patients with systemic lupus erythematosus. Isr Med Assoc J. 2011;13:333-7.
15. Oleksik AM, Ewing S, Shen W, van Schoor NM, Lips P. Impact of incident vertebral fractures on health related quality of life (HRQOL) in postmenopausal women with prevalent vertebral fractures. Osteoporos Int. 2005;16:861-70.
16. Ioannidis G, Papaioannou A, Hopman WM, Akhtar-Danesh N, Anastassiades T, Pickard L, et al. Relation between fractures and mortality: Results from the Canadian Multicentre Osteoporosis Study. CMAJ. 2009;181:265-71.
17. Kado DM, Browner WS, Palermo L, Nevitt MC, Genant HK, Cummings SR. Vertebral fractures and mortality in older women: A prospective study. Study of Osteoporotic Fractures Research Group. Arch Intern Med. 1999;159:1215-20.
18. Naves M, Diaz-Lopez JB, Gomez C, Rodriguez-Rebollar A, Rodriguez-Garcia M, Cannata-Andia JB. The effect of vertebral fracture as a risk factor for osteoporotic fracture and mortality in a Spanish population. Osteoporos Int. 2003;14:520-4.
19. Klotzbuecher CM, Ross PD, Landsman PB, Abbott 3rd TA, Berger M. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res. 2000;15:721-39.
20. Hallberg I, Bachrach-Lindstrom M, Hammerby S, Toss G, Ek AC. Health-related quality of life after vertebral or hip fracture: A seven-year follow-up study. BMC Musculoskelet Disord. 2009;10:135.
21. Angeli A, Guglielmi G, Dovio A, Capelli G, de Feo D, Giannini S, et al. High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: A cross-sectional outpatient study. Bone. 2006;39:253-99.
22. Li EK, Tam LS, Griffith JF, Zhu TY, Li TK, Li M, et al. High prevalence of asymptomatic vertebral fractures in Chinese women with systemic lupus erythematosus. J Rheumatol. 2009;36:1646-52.
23. Delmas PD, van de Langerijt L, Watts NB, Eastell R, Genant H, Grauer A, et al. Underdiagnosis of vertebral fractures is a worldwide problem: the IMPACT study. J Bone Miner Res. 2005;20:557-63.
24. Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures. Lancet. 2002;359:1761-7.
25. Gehlbach SH, Bigelow C, Heimisdottir M, May S, Walker M, Kirkwood JR. Recognition of vertebral fracture in a clinical setting. Osteopor Int. 2000;11:577-82.
26. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham 3rd CO, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010;69:1580-8.
27. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25:1271-7.
28. Prevoo ML, Hof MA v't, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38:44-8.
29. Esteve-Vives J, Batlle-Gualda E, Reig A. Spanish version of the Health Assessment Questionnaire: reliability, validity and transcultural equivalency. Grupo para la Adaptación del HAQ a la Población Española. J Rheumatol. 1993;20:2116-22.
30. Genant HK, Wu CY, van Kuijk C, Nevitt MC. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res. 1993;8:1137-48.
31. Mak A, Lim JQ, Liu Y, Cheak AA, Ho RC. Significantly higher estimated 10-year probability of fracture in lupus patients with bone mineral density comparable to that of healthy individuals. Rheumatol Int. 2013;33:299-307.
32. van Staa TP, Geusens P, Bijlsma JW, Leufkens HG, Cooper C. Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54:3104-12.
33. Ørstavik RE, Haugeberg G, Uhlig T, Mowinckel P, Falch JA, Halse JI, et al. Self reported non-vertebral fractures in rheumatoid arthritis and population based controls: incidence and relationship with bone mineral density and clinical variables. Ann Rheum Dis. 2004;63:177-82.
34. Wright NC, Lisse JR, Walitt BT, Eaton CB, Chen Z, Women's Health Initiative Investigators. Arthritis increases the risk for fractures - results from the Women's Health Initiative. J Rheumatol. 2011;38:1680-8.
35. De Vries F, Bracke M, Leufkens HG, Lammers JW, Cooper C, van Staa TP. Fracture risk with intermittent high-dose oral glucocorticoid therapy. Arthritis Rheum. 2007;56:208-14.
36. Vestergaard P, Olsen ML, Paaske Johnsen S, Rejnmark L, Sørensen HT, Mosekilde L. Corticosteroid use and risk of hip fracture: a population-based case-control study in Denmark. J Intern Med. 2003;254:486-93.
37. van Staa TP, Leufkens HGM, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int. 2002;13:777-87.
38. Walsh LJ, Lewis SA, Wong CA, Cooper S, Oborne J, Cawte SA, et al. The impact of oral corticosteroid use on bone mineral density and vertebral fracture. Am J Respir Crit Care Med. 2002;166:691-5.
39. Peel NF, Moore DJ, Barrington NA, Bax DE, Eastell R. Risk of vertebral fracture and relationship to bone mineral density in steroid treatment rheumatoid arthritis. Ann Rheum Dis. 1995;54:801-6.
40. Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids: potential mechanisms of their deleterious effects on bone. J Clin Invest. 1998;102:274-82.
41. Clark EM, Gould V, Morrison L, Ades AE, Dieppe P, Tobias JH. Randomized controlled trial of a primary care-based screening program to identify older women with prevalent osteoporotic vertebral fractures: Cohort for Skeletal Health in Bristol and Avon (COSHIBA). J Bone Miner Res. 2012;27:664-71.